ArticleProbiotics and antimicrobial proteins2026
Purification and Characterization of Gamma-Aminobutyric Acid (GABA) from E. faecium BS5 and Its Antidiabetic Efficacy in Streptozotocin-Induced Diabetic Rats.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A non-proteinaceous amino acid called GABA is well-known for its physiological uses and its role as an inhibitory neurotransmitter in the brain of mammals. Apart from its neurological function, GABA has been linked to blood pressure reduction and glucose balance modulation. Since β-cell destruction and decreased insulin secretion are hallmarks of diabetes mellitus, the natural production of GABA by pancreatic β-cells increases the possibility of its therapeutic role. The aim of this study was to produce, purify, and characterize GABA from glutamic acid and assess its potential as an antidiabetic, namely to impact β-cell proliferation. GABA was produced from glutamic acid using the enzyme glutamate decarboxylase (GAD). After that, the produced GABA was purified and characterized using different analytical methods. Furthermore, in vivo studies were carried out with diabetic mice to evaluate the effect of GABA treatment on β-cell proliferation and control of insulin levels. GABA treatment improved glycaemic control in diabetic mice by increasing β-cell proliferation and regulating glucagon and insulin production. These results demonstrate the potential of GABA as an antidiabetic drug and provide a safe substitute for traditional insulin injections. Further study is needed to understand its mechanism of action and investigate its therapeutic application in the treatment of diabetes.
Indexed as
Identifiers
40536745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.